Ribonexus

Oncology
Taking on the challenge of cancer drug resistance

Taking on the challenge of cancer drug resistance

Tumour survival, growth, and proliferation demand complex and broad biological capabilities, including proliferative signalling, evasion of growth suppressors, promotion of local blood vess

Oncology
Oncology 2023

Oncology 2023

Oncology 2023 features interviews, analysis, and commentary from pharmaphorum, industry leaders, and more

R&D
pharmaphorum podcast episode 83a

Restoring sensitivity to targeted therapies

In this new episode of the mini pharmaphorum podcast, web editor Nicole Raleigh spoke with Steven Powell, CEO of Ribonexus, a new company put together to develop and ultimately commercialis